Aclarion, Inc. (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company focused on chronic low back pain, published a shareholder letter from CEO Brent Ness on March 19, 2026. The letter details the company's strategic progress and key catalysts for 2026, including reimbursement initiatives, clinical trial milestones, and a strong balance sheet.
One of the primary goals for 2026 is pursuing reimbursement coverage from one or more regional insurance providers in the United States. This step is seen as crucial for broader payer adoption of the company's Nociscan platform. Nociscan uses magnetic resonance spectroscopy and proprietary augmented intelligence algorithms to help physicians identify painful discs in the lumbar spine, potentially optimizing treatment for chronic low back pain.
The company also anticipates an initial readout from the CLARITY clinical trial in the fourth quarter of 2026. This trial is expected to provide further clinical evidence supporting Nociscan's efficacy. Aclarion has been expanding commercial engagement with physicians and imaging centers, aiming to increase adoption of its technology.
Financially, Aclarion reports a strong balance sheet with cash runway extending into 2028, providing the resources needed to execute its strategic plan. The company has been making progress in both the United Kingdom and the United States regarding reimbursement, which is critical for widespread clinical adoption.
CEO Brent Ness emphasized disciplined execution against key catalysts that can expand Nociscan adoption and strengthen the clinical and reimbursement foundation. He noted increasing physician engagement and growing clinical evidence as positive indicators for the company's mission.
The full CEO Shareholder Letter is available on the company's website at https://www.aclarion.com. For more news from Aclarion, visit their latest news section at https://www.aclarion.com/news.
As a healthcare technology company, Aclarion is first addressing the chronic low back pain market with Nociscan, a SaaS platform that noninvasively aids physicians in distinguishing between painful and nonpainful discs. The platform receives MRS data from an MRI machine, processes it in the cloud using proprietary algorithms, and provides insights into pain sources.
The company's forward-looking statements indicate expectations for patient enrollment in ongoing clinical trials and potential benefits of Nociscan technology. However, these are subject to risks and uncertainties detailed in SEC filings.
